ASHP CEO Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP, has joined the American Nurses Foundation (ANF) Board of Trustees. ANF is the charitable and philanthropic arm of the American Nurses Association.
“Paul will bring a vital interprofessional perspective to our work to transform health
The American Society of Health-System Pharmacists (ASHP) is introducing a new set of targeted electronic practice resources for pharmacists. Each ASHP eReport offers concise, solution-oriented information addressing the wide range of challenges pharmacists face in daily practice.
The first se
Wisconsin took a significant first step toward provider status this month as Gov. Scott Walker signed legislation that allows pharmacists to take on patient care services.
Wisconsin Act 294 allows licensed pharmacists to perform patient care services delegated to them by a licensed physici
and Novartis on April 29 announced the approval of the tyrosine kinase inhibitor ceritinib for the treatment of advanced lung cancer.
According to the labeling (PDF) for ceritinib, the drug is indicated for the treatment of anaplastic lymphoma kinase-positive metastatic non-small-ce
April 1 called on the chief of FDA's drugs division to defend a proposal that
would allow makers of generic drugs to unilaterally update safety information
in their products' professional labeling.
Janet Woodcock, director of FDA's Center
for Drug Evaluation and Research, told member
hospital may have cracked the code for private-payer reimbursement of inpatient
medication therapy management (MTM) services provided by pharmacists.
Deborah Sanchez, director of pharmacy
practice and residency at 380-bed Asante Rogue Regional Medical Center in
Medford, said the hospita
Pharmacists’ direct engagement with patients whose diabetes mellitus had not been under control has helped a health care organization better serve this population and save money, metrics suggest.
The direct engagement is part of the collaborative practice protocol between the medical group and pha
Janssen Biotech on April 23 announced that FDA has approved siltuximab for the treatment of multicentric Castleman disease (MCD), a rare blood disorder that affects the lymph nodes.
About 1100–1300 Americans are estimated to have MCD, according to data cited by Janssen.
Siltuximab will be mark